湿法纳米研磨制备药物纳米晶体——铝碳酸镁

doi:10.16085/j.issn.1000-6613.2020-2179

化工进展 ›› 2021, Vol. 40 ›› Issue (10): 5699-5707.DOI: 10.16085/j.issn.1000-6613.2020-2179

湿法纳米研磨制备药物纳米晶体——铝碳酸镁

王小康¹^,²(), 张扬², FALOLA Akinola¹, 何运良¹, 王学重¹()

^1.北京石油化工学院新材料与化工学院，恩泽生物质精细化工北京市重点实验室，北京 102617
^2.华南理工大学化学与化工学院，广东广州 510640

收稿日期:2020-11-02 修回日期:2021-01-11 出版日期:2021-10-10 发布日期:2021-10-25
通讯作者: 王学重
作者简介:王小康（1994—），男，硕士研究生，研究方向为纳米药物。E-mail：201820121854@mail.scut.edu.cn。
基金资助:
国家自然科学基金重点项目(61633006);广东省应用型科技研发资金项目(2015B020232007);广东省自然科学基金(2017A030310262);广东省自然科学基金面上项目(2018A030313263);北京石油化工学院恩泽生物质精细化工北京市重点实验室开放课题(20201001)

Preparation of pharmaceutical nanocrystals using wet nanomilling—Hydrotalcite

WANG Xiaokang¹^,²(), ZHANG Yang², FALOLA Akinola¹, HE Yunliang¹, WANG Xuezhong¹()

^1.Beijing Key Laboratory of Enze Biomass and Fine Chemicals, College of New Materials and Chemical Engineering, Beijing Institute of Petrochemical Technology, Beijing 102617, China
^2.School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, Guangdong, China

Received:2020-11-02 Revised:2021-01-11 Online:2021-10-10 Published:2021-10-25
Contact: WANG Xuezhong

摘要/Abstract

摘要：

低溶出速率和溶解度严重影响其生物利用度和药效, 是造成药物研发候选化合物不能成药的首要因素。近年的研究发现，当颗粒粒径减小到100～200nm，其溶出速率和溶解度会出现显著提升。本文研究了利用湿法纳米研磨技术制备铝碳酸镁药物纳米晶体的工艺。铝碳酸镁是治疗胃病的有效药物，其纳米颗粒悬浮液抗酸效果更好，起效速度更快。本文选择了六偏磷酸钠为分散剂，利用湿法研磨机，考察了分散剂用量、研磨转速、铝碳酸镁含量、研磨时间等参数对颗粒粒度分布的影响规律，获得了在最佳的工艺操作条件为研磨转速3000r/min、研磨时间105min、主药体积分数2%、分散剂为固含量质量分数的1.5%时，成功得到粒径D₁₀(76.4nm)、D₅₀(161nm)、D₉₀(352nm)的铝碳酸镁纳米悬浮液。制酸力实验结果证明纳米铝碳酸镁悬浮液比微米级悬浮液在盐酸中的溶出速率快5倍以上。

关键词: 纳米药物, 湿法纳米研磨, 铝碳酸镁, 制酸力, 晶体

Abstract:

Low dissolution rate and solubility severely affects their bioavailability and efficacy and is the main factor that led to failure in the development of candidate drug compounds. Recent studies revealed that when the particle size is reduced to around 100—200nm, its dissolution rate and solubility significantly increase. Hydrotalcite is an effective API (active pharmaceutical ingredient) for treating gastric diseases. Its nanoparticle suspension shows a better anti-acid effect and a faster onset of action. In this study, preparation of hydrotalcite nanocrystals using wet nano milling technology was investigated. In the process, sodium hexametaphosphate was selected as a dispersant, and the impacts of dispersant dosage, grinding speed, hydrotalcite content, as well as grinding time on the particle size distribution were examined. An operational envelope was unveiled to obtain a hydrotalcite nano-suspension with D₁₀ (76.4nm), D₅₀(161nm), and D₉₀(352nm) with the grinding speed being 3000r/min, the grinding time 105 minutes, the main drug volume fraction 2%, and the dispersant being 1.5% of the solid content mass fraction. The acid-neutralizing capacity experimental result showed that the dissolution rate of the nano-hydrotalcite suspension in hydrochloric acid was 5 times faster than that of the micron-sized suspension.

Key words: nanomedicine, wet nano milling, hydrotalcite, acid-neutralizing capacity, crystals

中图分类号:

R943

王小康, 张扬, FALOLA Akinola, 何运良, 王学重. 湿法纳米研磨制备药物纳米晶体——铝碳酸镁[J]. 化工进展, 2021, 40(10): 5699-5707.

WANG Xiaokang, ZHANG Yang, FALOLA Akinola, HE Yunliang, WANG Xuezhong. Preparation of pharmaceutical nanocrystals using wet nanomilling—Hydrotalcite[J]. Chemical Industry and Engineering Progress, 2021, 40(10): 5699-5707.

图/表 13

图1 原料铝碳酸镁的粒度分布

图2 湿法研磨机照片和实验流程简图

图3 分散剂的加入量对最终粒度分布D50和D90的影响

图4 研磨前后悬浮液粒度分布和DPI对比

图5 马尔文3000和Horiba纳米粒度仪SZ-100测量的粒度分布对比

图6 粒度分布和累计粒度分布在研磨中的变化趋势

表1 研磨中粒度分布随时间的变化

t/min	D₁₀/μm	D₅₀/μm	D₉₀/μm
0	5.32	29.4	114
2	2.04	6.32	72.5
5	1.04	5.43	611
10	0.196	0.552	3.76
15	0.11	0.29	1.06
20	0.104	0.262	0.823
25	0.0981	0.236	0.712
30	0.0897	0.205	0.588
45	0.0832	0.183	0.482
60	0.0798	0.173	0.406
75	0.0772	0.164	0.374
90	0.0763	0.161	0.357
105	0.0764	0.161	0.352

图7 不同固含量下研磨60min时的粒度分布和不同固含量下D10、D50、D90的变化

图8 不同研磨转速下D50随时间的变化

图9 碳酸镁原料和研磨后纳米悬浮液SEM照片

图10 铝碳酸镁、研磨后悬浮液和六偏磷酸钠的XRD图谱

表2 不同粒度悬浮液的制酸力和制酸时间测定

取样时间 /min	铝碳酸镁 /g	水 /mL	盐酸 /mL	氢氧化钠 /mL	制酸力 /mL	制酸时间 /min
0	0.5	87.5	160	28	264	15
2	0.5	87.5	160	26	268	6
5	0.5	87.5	160	28	264	5
10	0.5	87.5	160	22	276	5
20	0.5	87.5	160	10	300	3
30	0.5	87.5	160	12	296	3
60	0.5	87.5	160	16	288	3

图11 不同时间制酸能力pH变化曲线

参考文献 23

1	SHEGOKAR R, MÜLLER R H. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives[J]. International Journal of Pharmaceutics, 2010, 399(1/2): 129-139.
2	LIPINSKI C. Poor aqueous solubility: an industry wide problem in drug discovery[J]. American Pharmaceutical Review, 2002, 5: 82-85.
3	MALAMATARI M, TAYLOR K M G, MALAMATARIS S, et al. Pharmaceutical nanocrystals: production by wet milling and applications[J]. Drug Discovery Today, 2018, 23(3): 534-547.
4	BUCKTON G, BEEZER A E. The relationship between particle size and solubility[J]. International Journal of Pharmaceutics, 1992, 82(3): R7-R10.
5	KHADKA P, RO J, KIM H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability[J]. Asian Journal of Pharmaceutical Sciences, 2014, 9(6): 304-316.
6	JUNYAPRASERT V B, MORAKUL B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs[J]. Asian Journal of Pharmaceutical Sciences, 2015, 10(1): 13-23.
7	GAO L, ZHANG D R, CHEN M H. Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system[J]. Journal of Nanoparticle Research, 2008, 10(5): 845-862.
8	GULSUN T, GURSOY R N, ONER L. Nanocrystal technology for oral delivery of poorly water-soluble drugs[J]. FABAD Journal of Pharmaceutical Sciences, 2009, 34: 55-65.
9	JUNGHANNS J U, MÜLLER R H. Nanocrystal technology, drug delivery and clinical applications[J]. International Journal of Nanomedicine, 2008, 3(3): 295-309.
10	RAGHAVA SRIVALLI K M, MISHRA B. Drug nanocrystals: a way toward scale-up[J]. Saudi Pharmaceutical Journal, 2016, 24(4): 386-404.
11	LU Y, LI Y, WU W. Injected nanocrystals for targeted drug delivery[J]. Acta Pharmaceutica Sinica B, 2016, 6(2): 106-113.
12	SHEOKAND S, REDDY V, BANSAL A K. Pharmaceutical nanocrystals: from fundamentals to advances[J]. Pharma Times, 2018, 50: 20-25.
13	TUOMELA A, LAAKSONEN T, LARU J, et al. Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications[J]. International Journal of Pharmaceutics, 2015, 485(1/2): 77-86.
14	AGIMELEN O S, SVOBODA V, AHMED B, et al. Multi-sensor inline measurements of crystal size and shape distributions during high shear wet milling of crystal slurries[J]. Advanced Powder Technology, 2018, 29(12): 2987-2995.
15	岳鹏飞, 刘阳, 谢锦, 等. 药物纳米晶体制备技术30年发展回顾与展望[J]. 药学学报, 2018, 53(4): 529-537.
	YUE Pengfei, LIU Yang, XIE Jin, et al. Review and prospect on preparation technology of drug nanocrystals in the past thirty years[J]. Acta Pharmaceutica Sinica, 2018, 53(4): 529-537.
16	谢元彪, 许俊男, 陈颖翀, 等. 纳米晶体技术在难溶性药物中的应用进展与思考[J]. 世界科学技术: 中医药现代化, 2016, 18(10): 1788-1793.
	XIE Yuanbiao, XU Junnan, CHEN Yingchong, et al. A progress and thinking on the application of nanocrystals technology to poorly soluble drugs[J]. Modernization of Traditional Chinese Medicine and Materia Medica—World Science and Technology, 2016, 18(10): 1788-1793.
17	STENGER F, GÖTZINGER M, JAKOB P, et al. Mechano-chemical changes of nano sized α-Al₂O₃ during wet dispersion in stirred ball Mills[J]. Particle & Particle Systems Characterization, 2004, 21(1): 31-38.
18	STENGER F, MENDE S, SCHWEDES J, et al. Nanomilling in stirred media Mills[J]. Chemical Engineering Science, 2005, 60(16): 4557-4565.
19	KWADE A. Wet comminution in stirred media Mills—Research and its practical application[J]. Powder Technology, 1999, 105(1/2/3): 14-20.
20	CERDEIRA A M, GANDER B, MAZZOTTI M. Role of milling parameters and particle stabilization on nanogrinding of drug substances of similar mechanical properties[J]. Chemical Engineering & Technology, 2011, 34(9): 1427-1438.
21	RAMACHANDRAN R, IMMANUEL C D, STEPANEK F, et al. A mechanistic model for breakage in population balances of granulation: theoretical kernel development and experimental validation[J]. Chemical Engineering Research and Design, 2009, 87(4): 598-614.
22	FALOLA A A, WANG X Z. On-line real-time characterisation of nanoparticle size distribution using a self-calibrating ultrasonic probe[C]//SRA Policy Forum Risk Governance for Key Enabling Technologies, Venice, Italy, 2017.
23	ZHANG L, CHAI G, ZENG X, et al. Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability[J]. Drug Development and Industrial Pharmacy, 2010, 36(9): 1054-1063.

[1]	陈欢欢, 高伟洪, 陈凯凯, 张之悦, 赵小燕. 光子晶体结构色纺织材料的制备及应用研究进展[J]. 化工进展, 2022, 41(8): 4327-4340.
[2]	陈博, 洪祺祺, 唐丽荣, 张伟川, 陈伟香, 李星, 吕日新, 黄彪. 无铅铜基钙钛矿Cs₂CuBr₄的湿度传感性能[J]. 化工进展, 2022, 41(6): 3162-3169.
[3]	陈博, 陈伟香, 唐丽荣, 洪祺祺, 严雪, 靳江涛, 吕日新, 黄彪. 基于硝化纳米纤维素/琼脂的高灵敏度湿度传感器[J]. 化工进展, 2022, 41(5): 2604-2614.
[4]	夏泽秋, 贺高红, 王林, 姜晓滨. 均匀水凝胶片层高效调控一水合尿酸钠晶习[J]. 化工进展, 2021, 40(2): 977-989.
[5]	梁高峰, 陈学青, 王德武, 张少峰, 刘燕, 张继军. 淘洗六水氯化铝过程中晶体沉降速度与纯化规律分析[J]. 化工进展, 2021, 40(1): 386-393.
[6]	韩飞, 贾里, 乔晓磊, 金燕, 樊保国. 镁渣晶体结构对脱硫活性影响实验[J]. 化工进展, 2019, 38(07): 3319-3325.
[7]	李丽, 刘宝树, 郑学明, 孙华. 舒巴坦钠溶析结晶工艺优化[J]. 化工进展, 2019, 38(06): 2905-2914.
[8]	尚泽仁, 胡卫国, 汤伟伟, 贾丽娜, 李鸣晨, 赵燕晓, 魏宁, 龚俊波. 离子液体在药物晶体工程中的应用[J]. 化工进展, 2019, 38(05): 2389-2401.
[9]	叶榆,张凯伦,霍地. 绿茶水热还原制备微纳米金属铜[J]. 化工进展, 2019, 38(03): 1487-1493.
[10]	冷帅, 李云涛, 邓建国. 三核铜配合物的合成、表征及其催化性能[J]. 化工进展, 2018, 37(10): 3879-3884.
[11]	寇东辉, 马威, 张淑芬, 王琳, 唐炳涛, 李爽. 一维光子晶体结构色材料的应用研究进展[J]. 化工进展, 2018, 37(04): 1468-1479.
[12]	李萍, 徐交, 陈胜利, 王爱军, 朱慧丽, 王媛. SiO₂ Opal光子晶体结构周期数对TiO₂染料敏化太阳能电池光电性能的影响[J]. 化工进展, 2017, 36(03): 881-886.
[13]	庄森炀, 唐丽荣, 卢麒麟, 林凤采, 倪沛钟, 黄彪. 磷酸锆辅助催化水解菌糠制备纳米纤维素晶体的性能[J]. 化工进展, 2016, 35(03): 866-871.
[14]	李淑云, 冯书晓, 章亚东. 茂钛配合物水解的研究手段[J]. 化工进展, 2016, 35(02): 364-368.
[15]	张超灿, 文斌, 董一笑, 吴立力. 快速磁响应光子晶体的研究进展[J]. 化工进展, 2015, 34(07): 1913-1918.

湿法纳米研磨制备药物纳米晶体——铝碳酸镁

Preparation of pharmaceutical nanocrystals using wet nanomilling—Hydrotalcite

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 13

参考文献 23

相关文章 15

编辑推荐

Metrics

本文评价